Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ceftazidimum inn - stungulyfs-/innrennslisstofn, lausn - 2 g

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ceftazidimum inn - stungulyfsstofn, lausn - 1 g

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - Æxlishemjandi lyf - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - ceftriaxonum dínatríum - stungulyfs-/innrennslisstofn, lausn - 1 g

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

grünenthal gmbh* - esomeprazolum natríum - stungulyfs-/innrennslisstofn, lausn - 40 mg

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - bleomycinum súlfat - stungulyfs-/innrennslisstofn, lausn - 15.000 a.e.

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - ceftriaxonum dínatríum - innrennslisstofn, lausn - 2 g

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf - voriconazolum inn - innrennslisstofn, lausn - 200 mg

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf.* - gemcitabinum hýdróklóríð - innrennslisstofn, lausn - 1000 mg

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

octapharma ab - human fibrinogen - stungulyfs-/innrennslisstofn og leysir, lausn - 1 g